Co-targeting mTORC and EGFR signaling as a therapeutic strategy in HNSCC

Head and neck squamous cell carcinomas (HNSCCs) are frequently altered along the PI3K/AKT/mTORC signaling axis. Despite excellent preclinical data, the use of compounds targeting this pathway as monotherapy has been underwhelming in initial clinical trials and identification of predictive biomarkers...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Cancer Ther
Hauptverfasser: Swick, Adam D., Prabakaran, Prashanth J., Miller, Margot C., Javaid, Amal M., Fisher, Michael M., Sampene, Emmanuel, Ong, Irene M., Hu, Rong, Iida, Mari, Nickel, Kwangok P., Bruce, Justine Y., Wheeler, Deric L, Kimple, Randall J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2017
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5505754/
https://ncbi.nlm.nih.gov/pubmed/28446642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0115
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge